BPH Global Ltd

Sale of Platform in East Johor Strait

Further to previous announcements made by the Board of BPH Global Ltd (ASX: BP8) (Company) regarding its strategic review of the Company’s seaweed operations, the Board is pleased to announce that the Company has entered into an agreement for the sale of the floating platform in the East Johor Strait.


Highlights

  • BP8 sells the floating platform in the East Johor Strait.
  • Sale proceeds a boost to the Company’s cashflow position
  • Relocation of seaweed R&D activity
Background

The Company’s ongoing strategic review of its seaweed operations has included an in-depth, thorough review of the viability of the floating platform in the East Johor Strait. It has been a significant legacy issue for the new management team since the Company re-commenced trading on the ASX in late March this year.

The floating platform is owned by SCU-RY Farm Pte. Ltd. (SCU-RY), a joint venture company incorporated for the purpose of acquiring and operating the floating platform. The BP8 Group through the Singapore-based subsidiary Stemcell United Pte. Ltd. (SCU-SG) holds 70% of the issued capital of SCU-RY, and Rong-Yao Fisheries Pte. Ltd. (RY) the remaining 30% (in aggregate, the Sale Shares).

In conducting its review of the viability of the floating platform, the Company considered a range of potential options, including: operation of the platform in its current position; dismantling the platform or selling the platform to a third party.

Operating the platform for the purposes of growing seaweed would have cost the Company approximately SGD15,000 per month, a very significant sum given the challenges the Company endured in its efforts to farm seaweed on a commercial basis in the East Johor Strait. The Board concluded that seaweed could not be cultivated and harvested on a commercial basis in the East Johor Strait. Dismantling the platform would have cost a minimum of SGD150,000. Given these alternatives, the Company focused its efforts on locating a buyer for the platform.


Click here for the full ASX Release

This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.


The Conversation (0)
Recce Pharmaceuticals

Japan Patent Allowance for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041.

Keep reading...Show less
Completion of Indonesian Seaweed Joint Venture Transaction

Completion of Indonesian Seaweed Joint Venture Transaction

BPH Global (BP8:AU) has announced Completion of Indonesian Seaweed Joint Venture Transaction

Download the PDF here.

Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Latest Press Releases

Related News

×